Evaxion Strengthens Financial Position with New Capital
Evaxion A/S (NASDAQ: EVAX), a clinical-stage TechBio company renowned for its AI-Immunology™ powered vaccines, has recently enhanced its financial stability by successfully raising $7.2 million. This increase in funding is attributed to a combination of share sales totaling $4.5 million and the exercise of warrants, which contributed an additional $2.7 million.
Capital Inflow and Its Implications
The latest fundraising efforts have culminated in a total gross cash inflow of $14.7 million since the conclusion of the second quarter of 2025. With this funding, Evaxion is now well-equipped to support its operational needs and research and development programs well into the second half of 2027, significantly extending their financial runway.
Details of the Funding
In recent weeks, Evaxion's financial maneuvers have proven fruitful, with strong interest from investors. The funding was achieved through an at-the-market (ATM) offering alongside the exercise of investor warrants, highlighting investor confidence in the company’s future prospects.
Enhancing Operational Cash Position
The capital influx not only boosts Evaxion's cash reserves, which now stand to sustain their strategic initiatives, but it also reinforces the company’s equity position. Just last month, Evaxion received $7.5 million from MSD (the trade name for Merck & Co., Inc.) following the licensing of their vaccine candidate EVX-B3, further bolstering their resources.
Statements from Management
Expressing gratitude for the support, CFO Thomas Schmidt stated, “We are pleased to have bolstered our cash position thereby extending our runway into the second half of 2027, allowing us to fully focus on executing our strategy and plans.” This confidence reflects the company's commitment to advancing its innovative product pipeline with renewed vigor.
Current Financial Situation
The recent exercises of investor warrants have resulted in the reduction of outstanding warrants to purchase Evaxion’s American Depositary Shares (ADSs) by 1.0 million. Currently, the total number of outstanding warrants stands at 2.8 million, with a weighted average exercise price of $10.94, a promising indicator for future capital raising efforts.
Projected Operational Spending
In assessing their financial forecasting, Evaxion anticipates an operational cash expenditure of approximately $14 million for the ongoing fiscal year. With the existing cash resources and recent inflows, the company is positioned to navigate its financial commitments effectively.
Addressing Debt and Financial Health
As part of their financial restructuring, Evaxion reported a debt of $9.2 million at the end of the second quarter of 2025. In a strategic move to reduce this debt, they entered into a debt-to-equity conversion agreement with the European Investment Bank in July 2025, which effectively lowered their obligations by $4.1 million and improved their equity base.
Contact Information
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai
About Evaxion A/S
Evaxion is at the forefront of the TechBio sector, leveraging its proprietary AI-Immunology™ platform to revolutionize vaccine development. This advanced AI technology allows the company to decode the intricacies of the human immune system, creating novel immunotherapies aimed at treating various diseases including cancer, bacterial infections, and viral outbreaks.
Innovative Approach to Vaccine Development
By harnessing the capabilities of artificial intelligence, Evaxion is crafting a pipeline of personalized vaccines designed for oncology and infectious diseases, focusing primarily on those areas that present high unmet medical needs. The company is on a mission to transform patient care through innovative and targeted treatment strategies.
Frequently Asked Questions
What is the purpose of Evaxion's recent funding?
The funding aims to support Evaxion's operations and research and development initiatives through 2027, ensuring sustained growth and product development.
How much did Evaxion raise in total recently?
Evaxion raised a total of $7.2 million through share sales and the exercise of investor warrants.
What will the impact of this funding be on Evaxion's operations?
This funding will enable Evaxion to fully focus on executing its strategic plans and advancing its vaccine pipeline without financial constraints.
What is the current debt situation of Evaxion?
Evaxion reported a debt of $9.2 million, which has been reduced significantly as part of a debt-to-equity conversion with the European Investment Bank.
What is Evaxion's unique approach to vaccine development?
Evaxion utilizes its AI-Immunology™ platform to decode the human immune system, creating personalized vaccines for challenging diseases, including cancer and infections.
